Drug
Taletrectinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | ROS1 targeting TKI |
| Mechanism of Action | ROS1 inhibitor |
| Half-life | 66 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
ROS1 TKIs predominantly interact additively rather than synergistically with ionizing radiation, lacking the reinforcement in cellular injury that would drive a major theoretical increase in normal-tissue side effects (Jost et al. Neoplasia 2022). Despite this favorable radiobiological profile, the class's inherent adverse events—such as pneumonitis, gastrointestinal symptoms, and neurologic events—could theoretically compound with radiation-induced inflammation in overlapping treatment fields (Desilets et al. Cancer 2025; Jiang et al. Frontier Pharmacology 2025; Barbato et al. Clinical Cancer Research 2024).
Data on this page refer exclusively to patients treated with
Taletrectinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
ROS1 targeting TKI group page.